

Citation for published version:

Pauling, JD, Saketkoo, LA, Matucci-Cerinic, M, Ingegnoli, F & Khanna, D 2019, 'The patient experience of Raynaud's phenomenon in systemic sclerosis', *Rheumatology*, vol. 58, no. 1, key026, pp. 18-26.
<https://doi.org/10.1093/rheumatology/key026>

DOI:

[10.1093/rheumatology/key026](https://doi.org/10.1093/rheumatology/key026)

Publication date:

2019

Document Version

Peer reviewed version

[Link to publication](https://doi.org/10.1093/rheumatology/key026)

This is a pre-copyedited, author-produced version of an article accepted for publication in *Rheumatology* following peer review. The version of record John D Pauling, Lesley Ann Saketkoo, Marco Matucci-Cerinic, Francesca Ingegnoli, Dinesh Khanna; The patient experience of Raynaud's phenomenon in systemic sclerosis, *Rheumatology*, key026, is available online at: <https://doi.org/10.1093/rheumatology/key026>.

University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

The patient experience of Raynaud's phenomenon in systemic sclerosis

JD Pauling^{1,2} LA Saketkoo³, M Matucci-Cerinic⁴, F Ingegnoli⁵, D Khanna⁶

¹ Department of Pharmacy and Pharmacology, University of Bath, Bath, UK

² Royal National Hospital for Rheumatic Diseases, Bath, UK

³ University of Tulane Medical Center, New Orleans, LA, USA

⁴ Dept of Experimental and Clinical Medicine, University of Florence & Dept of Geriatric Medicine, Div of Rheumatology, AOUC, Florence, Italy

⁵ Division of Rheumatology, ASST Pini, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy

⁶ Division of Rheumatology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA

Short running title: The Patient Experience of SSc-RP

Correspondence to: John D Pauling, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Foundation Trust, Upper Borough Walls, Bath, BA1 1RL. E-mail: JohnPauling@nhs.net.

Abstract

Raynaud's phenomenon (RP) is the commonest manifestation of systemic sclerosis (SSc) and a major cause of disease-related morbidity. This review provides a detailed appraisal of the patient experience of SSc-RP and potential implications for disease classification, patient-reported outcome (PRO) instrument development and SSc-RP clinical trial design. The review explores the clinical features of SSc-RP, the severity and burden of SSc-RP symptoms and the impact of SSc-RP on function, work and social participation, body image dissatisfaction and health-related quality of life in SSc. Where management of SSc-RP is concerned, the review focuses on the "patient experience" of interventions for SSc-RP, examining geographic variation in clinical practice and potential barriers to the adoption of treatment recommendations concerning best-practice management of SSc-RP. Knowledge gaps are highlighted that could form the focus of future research. A more thorough understanding of the patient experience could support the development of novel PRO instruments for assessing SSc-RP.

Key words: Systemic sclerosis, Raynaud's phenomenon, Patient experience, Health-related Quality of Life, Disability, Function, Impact

Key messages

- 1) RP is the commonest and typically earliest clinical manifestation of SSc.
- 2) SSc-RP causes distressing physical symptoms, impaired function, body-image dissatisfaction and reduced health-related quality of life.
- 3) Patient-reported outcome measures that more fully capture the patient experience of SSc-RP are needed.

Introduction

Raynaud's phenomenon (RP) is the commonest manifestation of systemic sclerosis (SSc), affecting approximately 96% of patients (1). SSc-RP is also typically the earliest clinical manifestation of SSc, with a lag period that can last several years before additional organ-specific disease manifestations emerge (1, 2). Many comprehensive and valuable reviews have been prepared on the subject of SSc-RP, the majority of which have focused on current advances in elucidating the pathogenesis of SSc-RP and evidence-based approaches to management. A broad definition of RP (episodic digital ischaemia, characterised by pain, numbness and digital colour changes, and provoked by cold exposure and/or emotional stress) is typically recited, alongside reference to the "significant morbidity" associated with SSc-RP. This review provides a more detailed appraisal of the patient experience of SSc-RP and potential implications for disease classification, patient-reported outcome (PRO) instrument development and SSc-RP clinical trial design. The focus and scope of the review was not amenable to systematic review methods but individual comprehensive literature searches (including detailed grey searches of cited papers) were undertaken for each of the sub-headings applied to ensure a comprehensive appraisal of the patient experience of SSc-RP was achieved using a diverse range of sources that included cross-sectional studies, observational studies, registry analyses and clinical trial data. References to primary RP, when applied, are primarily used to compare and contrast the patient experience of primary RP with that of SSc-RP, or where evidence for SSc-RP is lacking. Where management of SSc-RP is concerned, this review focuses on the "patient experience" of interventions for SSc-RP, examining geographic variation in clinical practice and potential barriers to the adoption of treatment recommendations. Where applicable, knowledge gaps are highlighted that could form the focus of future research.

Sensory symptoms of SSc-RP

Population-based studies of RP (mainly primary) have identified numbness of the fingers as the subjective symptom most commonly associated with RP attacks (93.7%), with a lower rate of tingling (53.2%) and comparatively low levels of pain (27.6%) (3). In contrast, pain appears to be the predominant symptom associated with SSc-RP, perhaps reflecting a greater degree of tissue ischaemia in SSc compared to primary RP (4). Median pain visual analogue scores (VAS) are higher in SSc-RP compared to suspected connective tissue diseases (CTD)-RP and primary RP (4). Importantly, the same study reported lower overall RP "severity" scores in SSc compared to suspected CTD-RP, possibly indicating some degree of

habituation to peripheral vascular symptoms in SSc, and also highlighting the impact of item wording on responses generated for any given conceptual framework (4). More frequent episodes of SSc-RP was one of a small number of disease-specific variables (alongside digital ulcers, gastrointestinal symptoms and synovitis) that was independently associated with increased pain (assessed using an 11-point numerical rating scale) in SSc (5). Moreover, pain VAS scores aligned with SSc-RP activity scores during factor analysis of data obtained from a large clinical trial of SSc-RP, indicating they have strong inter-correlations and are measuring conceptually similar aspects of disease activity (6). In addition to pain, a number of additional sensory symptoms that might be attributable to SSc-RP have emerged from previous qualitative research examining the patient experience in SSc (mainly focussing on quality of life and function) including impaired touch function, numbness, sensations related to skin, increased sensibility, loss of sensory functions, and reduced tactile sensations in the fingers (7-9). The physical symptoms of SSc-RP are important to patients with SSc, with RP and difficulties experienced in cold weather listed as 2 of the 3 most frequently stated physical symptoms present in SSc (10). No qualitative research studies to date have exclusively explored the patient experience of SSc-RP. Little is known about the evolution of sensory symptoms of SSc-RP with disease progression.

Digital colour changes of SSc-RP

Maurice Raynaud provided the first detailed description of the digital colour changes that accompany impaired digital perfusion in the phenomenon to which he is eponymously linked (11). Digital pallor (ischaemic blanching secondary to vasoconstriction of the pre-capillary arterioles), cyanosis (deoxygenation of sequestered blood following constriction of the post-capillary venules) and rubor (a post-ischaemic reactive hyperaemic phenomenon) comprise the “tri-phasic” digital colour change response that might occur during RP attacks as they develop and abate (Figure 1). In practice, tri-phasic colour changes are not typical in RP, and certainly not essential for diagnosis. A large community-based questionnaire study, estimated the overall prevalence of RP (based on cold sensitivity with white and/or blue digital colour changes) at 4.6%, however insistence on a tri-phasic digital colour response would have seen the prevalence fall to ~0.1% (12). Population-based assessment of digital colour changes have identified ‘uni-phasic blanching’, ‘bi-phasic blanching with cyanosis’ and ‘bi-phasic blanching with rubor’ as the commonest combinations of digital colour changes reported across the spectrum of RP (3). The UK Scleroderma Study Group proposed a consensus classification approach to RP which was subsequently

tested in a small (n=30) cohort of healthy controls, primary and secondary RP (13). The proposed presence of repetitive episodes of bi-phasic (unspecified) colour changes in either cold or normal environments has subsequently been adopted in proposed classification criteria for RP and SSc (14-16). A recent international Delphi exercise of SSc-RP experts (n=12), meanwhile, specified the presence of 'biphasic *blanching and cyanosis*' of the digits to diagnose RP (17).

Few studies have specifically reported the digital colour changes associated with SSc-RP compared with other forms of RP. It has been suggested that cyanosis without blanching is more common in patients with SSc-RP than primary forms of RP (18). Reactive hyperaemia, meanwhile, appears to be less common in SSc-RP than in primary RP, and may reflect an irreversible obliterative microangiopathy incapable of post-occlusive vasodilation (19). A recent small study (n=20) identified uni-phasic digital colour changes (blanching in 91%, cyanosis in 9%) in over half (55%) of patients with SSc which has implications for our current approach to disease classification (4). There was, however, a higher rate of tri-phasic RP symptoms in SSc in comparison with primary RP (20% vs 5.1%) (4). The impact of strict adherence on bi-phasic digital colour changes on disease classification in early SSc and estimates of prevalence of SSc-RP has not previously been explored. The clinical correlates of specific digital colour changes, and combinations thereof, in SSc (such as associations with SSc-RP severity, disease duration and presence of digital ulcer (DU) disease) is unknown but might provide a readily assessed, and hitherto unused, tool for assessing peripheral vascular risk in SSc. For example, digital cyanosis has been shown to correlate with the presence of giant capillaries and microhaemorrhages on nailfold capillaroscopy in one study (4). The clinical features present within a small group of patients negative for both anti-nuclear antibodies and SSc-RP from the EUSTAR registry raised the possibility of alternative pathology and the absence of RP symptoms should prompt further diagnostic inquiry to exclude sclerosing skin conditions that can mimic SSc (20). Gender-specific differences in digital colour changes of RP have not been explored in SSc. Population-based studies of primary RP symptoms suggest uni-phasic blanching is commoner in females (75% vs. 58%) whereas bi-phasic blanching with rubor is commoner in males (29% vs. 10%) (3).

Body areas affected

The fingers are the most commonly affected body area in RP and symptoms are bilateral in 90% of patients (4). Asymmetry can be a predictor of secondary RP (21). Relative sparing of the thumbs occurs across all

forms of RP (4, 22), although the extent of thumb involvement assessed using thermal imaging appears to be more exaggerated in secondary RP compared with primary RP (23). Symptoms affecting the earlobes and nose, meanwhile, appear to be more common in primary RP (19).

Precipitating and aggravating factors

Typical descriptions of RP, describe episodic vasospasm occurring in response to cold exposure and/or emotional stress. Cold appears to be the more important precipitating event in SSc-RP. A questionnaire-based study of SSc-RP, reported cold being a precipitating factor in all participants (n=18) whereas only 1/3 also reported attacks provoked by emotion (24). These findings were replicated in a recent larger survey of a mixed population of RP (n=443) that reported cold exposure as the trigger for RP attacks in 91% of subjects overall (95% in secondary RP) and emotional stress in 30% (25). Changes in ambient temperature were an associated event in 87% of SSc-RP attacks in an early physiological study that incorporated ambulatory temperature measurement; compared with only 65.9% of attacks in primary RP where a higher proportion of attacks appeared to have been precipitated by emotional stress (26). It was also noted that patients with primary RP reporting higher stress ratings prior to RP attacks often had higher digital skin temperatures throughout RP attacks (26). The apparent relationship between pre-RP attack stress and skin temperature during RP attacks that was not replicated in SSc (26). Physiological studies have also identified an increase in physiological markers of stress (such as muscle tension and tachycardia) during SSc-RP attacks that is not observed in primary RP attacks (26). In this regard, emotional stress might propagate rather than precipitate attacks of SSc-RP. Thematically relevant emotional stressors might specifically aggravate RP. For example, imagination of the threat of cold exposure (subjects were asked to imagine loss of gloves and car keys during a snowstorm) has been shown to induce reduced finger temperature in RP patients but not healthy controls (27). Differences in precipitating events of attacks in primary RP and SSc-RP might explain disparity in responses to behavioural intervention for RP. For example, finger temperature biofeedback intervention (patients trained to augment the temperature of the fingers using a sinusoidal tone that varied according to finger temperature) resulted in reductions in RP attack frequency in primary RP but no such response to biofeedback intervention was observed in SSc (28).

Tobacco use has implications for peripheral vascular complications of SSc. Smokers with SSc are also 3-4 times more likely to require surgical or pharmacological intervention for digital ischaemia than non-smokers (29). The relationship between smoking and peripheral vascular compromise appears to extend to RP severity. Use of the Comprehensive Smoking Index identified a significant association between smoking intensity (packs/day) and SSc-RP severity but the effects dissipated within 1 year of smoking cessation; highlighting the importance of this non-pharmacological intervention in SSc-RP (30).

Frequency of RP attacks

Analysis of clinical trial data provides some insight into the average daily frequency of RP attacks experienced (or at least captured using diary monitoring) by patients with SSc; although trials are often enriched with patients with more severe SSc-RP (e.g. eligibility criteria mandating exceeded thresholds for mean daily average RP attack frequency prior to randomisation) which means the data might be less applicable to real-life (31-33). Some studies have also incorporated the presence of digital ulcers as an inclusion criteria for study entry into SSc-RP trials (34). For example, diary returns from RCTs of SSc undertaken during the Winter months and/or requiring a minimum of >4-8 RP attacks per week prior to enrolment have reported mean daily frequency of RP attacks of between 3.3 and 4.1 attacks/day (6, 31, 32, 35, 36), or approximately 28 attacks per week (34). Studies of mixed populations of primary and secondary RP, sometimes applying similar approaches have revealed a slightly lower mean daily attack frequency of 1.9-2.8 attacks/day (37, 38). In contrast, a cross sectional study of SSc that enrolled patients with SSc throughout the year and did not require a minimum threshold number of RP attacks prior to enrolment, meanwhile, revealed a lower mean daily number of attacks of only 2/day (39). Unsurprisingly, seasonal variation in weather influences attack burden in SSc-RP. A small (n=18) longitudinal study identified doubling in the daily frequency of RP attacks (2.9 vs. 1.5 attacks/day) during Winter compared to Summer despite similar rates of outdoor exposure across seasons (24). This study also highlighted the persistent nature of SSc-RP with only 16.7% of respondents reporting no attacks during assessment in the Summer (24). Seasonal variation in weather and temperature fluctuations induced by air-conditioning have emerged as contributing to SSc-RP symptom burden in qualitative research (40, 41). The relationship between RP attack frequency and Raynaud's classification has varied between studies; with individual papers reporting higher, similar and lower RP attack frequency in primary RP compared to secondary RP (26, 39, 42). Gender may influence frequency of RP attacks with significantly fewer RP attacks reported in

males in one study of primary RP and SSc (39). The frequency of RP attacks does not appear to be higher in patients with DU (6). Diary monitoring of SSc-RP symptoms is laborious for patients and SSc-experts have expressed concerns regarding the respondent burden and value of this approach (43).

Duration of RP attacks

The duration of RP attacks over a 2-week RCS diary collection has been relatively consistent across studies with studies reporting mean daily aggregate duration spent in RP attacks of between 37-95 minutes/day, equating to average attack duration of ~15-20 minutes per attack (6, 31, 32, 44). Seasonal variation is again relevant with a lower mean daily duration of attacks of ~20 minutes daily in a study whose enrolment spanned Winter and Summer (36). The aforementioned longitudinal study examining the impact of seasonal variation on SSc-RP symptoms identified an approximate doubling in the aggregate daily duration (70 vs. 35 minutes/day) of attacks during Winter compared to Summer, despite similar rates of outdoor exposure (24). The duration of RP attacks does not appear to be higher in patients with active DU (6). Diary methods of assessing the frequency and duration of SSc-RP assume a paradigm of episodic RP attacks and preclude adequate capture of a phenomenon familiar to SSc clinicians and previously described by Jill Belch as “what is for many patients the worst feature of the disease - continual digital ischaemia” (45). The phrase “my constant companion” was used by a patient to describe SSc-RP in one qualitative research study to allude to the persistent threat and/or presence of digital ischaemic symptoms experienced by many patients with SSc (8).

Ability to prevent and manage RP attacks

Management of RP usually includes advice on the use of gloves and hand warmers but evidence examining the adoption and efficacy of such self-management approaches in preventing/shortening RP attacks is lacking. Measures to avoid or ameliorate SSc-RP attacks might influence diary returns concerning RP attack frequency and duration, which might have implications for the value of such parameters as clinical trial endpoints. Approximately 2/3 of patients with secondary RP report the ability to predict the occurrence of at least half of their RP attacks, with a similar proportion being able to predict attack severity based on environmental factors surrounding an attack (25). Nonetheless, the majority of patients with secondary RP report difficulty preventing or controlling the occurrence of RP attacks (25). This might indicate preventative therapeutic approaches might be preferable to treatment strategies

designed to ameliorate an attack when it occurs e.g. application of topical vasodilating gels that have been the subject of clinical trials for SSc-RP (37). The use of gloves and hand warming devices are considered helpful but it has been noted that no intervention prevents all attacks, and barriers to wearing gloves such as sclerodactyly and dressings have been identified (8).

The severity of SSc-RP

Raynaud's severity is a broad and challenging concept to measure and attempts to achieve this in the clinical trial setting have relied upon patient-reported outcome (PRO) instruments such as the RP VAS global assessment (focus on *difficulty* with Raynaud's), the Raynaud's severity scale (RSS) and the Raynaud's Condition Score (RCS) (Table 1). The RSS and RCS are single-item scales that ask patients to consider the *difficulty* patients have had because of their SSc-RP, considering the frequency and duration of attacks, pain, numbness and impact of SSc-RP on function when considering their score. It is not known which domains have the greatest influence on patient response and whether different patients focus on different domains when choosing their score. Despite differences in item wording and recall period (Table 1), mean values of these global assessments are remarkably consistent at around 4.4 on a 0-10 NRS across a number of studies (generally undertaken in Winter and requiring a minimum number of RP attacks during run-in phase) irrespective of the instrument used (RSS ~4.4 (34), RCS (UK) ~4.2 (32), RCS (US) 4.3 (6, 31) and an RCS of 46mm when captured using 0-100mm VAS (45). Furthermore, patient and physician global assessments of RP produce similar weighting for RP severity (1.37 and 1.36 on 0-3.0 scale; also equating to ~4.5 on 0-10 NRS) (6, 31). Mean RCS scores of ~2.0 have been obtained from studies that enrolled SSc patients throughout the year and have not mandated a minimum threshold of RP attacks to be experienced prior to study entry (39). Principal components factor analysis identified strong inter-correlation between the RCS score and other patient-reported RP VAS subscales (e.g. the SHAQ RP VAS) but not with physician assessment of RP by VAS, which appeared to have stronger inter-correlation with reported frequency and duration of RP attacks (6). Furthermore, factor analysis did not identify strong inter-correlation between the RCS score and the frequency/duration of RP attacks, suggesting patient assessment of the overall severity of RP and the frequency/duration of RP attacks are separable conceptually (6). Raynaud's severity assessed using the RCS was noted to be higher in patients with DU (5.03 vs. 4.1), although the wording of the item question in this work specifically asked subjects to include symptoms arising from "painful sores" when choosing their score (Table 1) (6). The severity of RP (based

on mean baseline RCS) has been shown to be the same in patients whether or not they are receiving vasodilator therapy for their RP (~45mm on 100mm VAS) (46) and similar for patients with primary RP and SSc (39). Severity of SSc-RP may differ amongst different ethnic groups with one study identifying higher severity of SSc-RP in native North-American populations (47).

Impact of SSc-RP on functional capacity

SSc-RP has consistently emerged as the highest-impact disease-specific manifestation of SSc in terms of both frequency and impact on ability to carry out everyday activities in patient surveys undertaken in North America, Europe and South America (48-50). The strong association between patient-reported assessment of RP severity and measures of function such as the Health Assessment Questionnaire (HAQ) and Scleroderma Functional Score are cited as evidence of the contribution of SSc-RP to disability; particularly concerning domains concerning hand function (6, 51). The impact of RP on functional capacity appears to be greatest for secondary RP, with a higher proportion of patients making adjustments to activities of daily living to accommodate RP symptoms (87% vs. 71%) compared to primary RP (25). Clinical trials of SSc-RP have demonstrated beneficial effects on functional capacity, sometimes in the absence of improvement in RCS diary parameters, suggesting functional impairment secondary to SSc-RP might be responsive to vasodilator therapy (34, 52). The impact of SSc-RP on function is captured with the Scleroderma HAQ (SHAQ) RP VAS subscale which enquires about the extent to which SSc-RP interferes with activities. Clinical trial data has identified a mean score of 1.15 units (on a 0-3 scale), allowing some quantification of the impact of SSc-RP on activities of daily living (6, 53). The SHAQ RP VAS is higher in SSc patients with digital pitting scars, digital tip ulcers and digital gangrene (6, 53).

Impact of SSc-RP on quality of life

A large patient survey ranked SSc-RP the highest of the organ-specific manifestations of SSc in terms of impact on quality of life and perception of illness severity (54). Quality of life appears to be affected to a greater extent by secondary RP than primary RP (6.5 vs. 5.2 on 0-10 NRS) (25). Furthermore, people with secondary RP also predict a greater improvement in quality of life when asked to imagine life without RP than people with primary RP (25).

The psychosocial impact of SSc-RP

No qualitative research studies to date have exclusively explored the patient experience of SSc-RP but SSc-RP themes have emerged in studies of SSc exploring quality of life, functioning and body image dissatisfaction. The socially isolating and psychological impact of SSc-RP is evident in the following quote taken from (55):

“If it’s 20 degrees below zero outside, you don’t go out at all . . . then I was really depressed, because it was so cold for such a long time. I didn’t go out to get my mail from the mail box for almost three weeks.”

Body image dissatisfaction related to SSc-RP (and the reaction of others) has also emerged in qualitative research, as the following quotes attest:

“What bothers me most? Of course the symptoms of the Raynaud’s syndrome bother me, the fact that my hands become blue, the fact that I don’t look at them when I go out in cold weather, the fact that I look at the hands of all people. But mostly the psychological issues bother me.” (55)

“When I’m on public transport and I pay for my bus ticket, when I stretch out my purple hand and the seller looks strangely at me, I no longer want to stretch out my hand.” (7)

The appearance of SSc-RP might have influenced the inclusion of items developed for the Body Concealment Scale for Scleroderma such as “I wear gloves to hide my hands”; “I wear make-up to hide skin discoloration”; “I avoid shaking hands with people” and “I hide my hands so that people don’t see them” and it should not be assumed that body image dissatisfaction pertains solely to the disfiguring effects of skin fibrosis and cutaneous ulceration in SSc (56).

SSc-RP is a factor influencing work participation and often requires adapting the work environment and wearing adequate clothing to avoid cold exposure (40). Some patients avoid disclosing their SSc diagnosis to avoid feeling different to other colleagues, concern about employer reaction and/or possible impact on career trajectory (40, 57). Travelling to and from work can represent a barrier to work participation due to the distressing effects of cold-exposure e.g. de-icing the car (40).

Barriers to therapeutic intervention

Considering the prevalence and impact of SSc-RP, registry data suggests the range of therapeutic options available for the management of SSc-RP is not fully exploited in terms of initiation of treatment and optimal therapeutic dosing (58). There is marked variation in the “patient experience” of therapeutic intervention for SSc-RP which relates to a number of factors. Physician attitudes to therapeutic intervention might be relevant with one survey reporting 20% of scleroderma experts considering less than half of their patients requiring treatment for their SSc-RP (59). Such attitudes might offer an explanation for wide variation in prescribing practices for SSc-RP (60). Calcium channel blockers (CCBs) are generally considered first-line therapy for SSc-RP (59, 61) and yet registry analyses suggest only 47-60.9% of patients with SSc ever receive CCB therapy for SSc-RP (62, 63). Vasoactive drug use varies according to disease-specific organ manifestations and is higher in patients with pulmonary arterial hypertension (84.7%) and digital ulcer disease (76.4%), than in patients with SSc-RP alone (58.1%); possibly reflecting physician attitudes to the relative importance of therapeutic intervention for SSc-RP (63). Marketing authorisation approval and challenges securing reimbursement has also contributed to marked geographic variation in practice with intravenous iloprost use for SSc-RP ranging from 1.3% in North America to 21.1% of patients in Europe (62, 63). Patient surveys suggest secondary RP is more readily treated with vasoactive drugs than primary RP (64% vs. 33%) but the effectiveness of vasoactive treatment is rated modestly with only 21% of secondary RP respondents considering their RP treatment “effective” (25). Smoking doesn’t appear to influence vasoactive therapy use for SSc-RP (30). Surveys have identified limited utilisation of validated PRO instruments for SSc-RP in clinical practice which has limited the emergence of practice-based evidence to ascertain the comparative efficacy of different vasodilator approaches to SSc-RP management (43, 58).

Conclusions

SSc-RP is the commonest disease-specific manifestation of SSc and is associated with considerable disease-related morbidity across a broad set of domains including pain, impaired hand function, reduced social participation, body image dissatisfaction, increased reliance on others and reduced quality of life. There are limitations to the current approaches for assessing SSc-RP. An enhanced understanding of the patient experience of SSc-RP might support the development of novel approaches to the assessment of SSc-RP that more fully captures the patient experience of SSc-RP and facilitates a more discerning appraisal of the efficacy of therapeutic intervention.

Acknowledgements

We wish to thank Professor Ariane Herrick for her helpful comments drafting the manuscript.

Funding: This work has not received direct funding but shall support the efforts of the Scleroderma Clinical Trials Consortium Vascular Working Group to develop improved methods for assessing Raynaud's phenomenon in systemic sclerosis. D Khanna is supported by National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases K24 AR063120 Award.

Disclosure statement: The authors have declared no conflicts of interest.

References

1. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. *Ann Rheum Dis*. 2007;66(6):754-63. doi: 10.1136/ard.2006.062901. PubMed PMID: 17234652; PubMed Central PMCID: PMC1954657.
2. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. *Arthritis Rheum*. 2013;65(8):1953-62. doi: 10.1002/art.37988. PubMed PMID: 23666787.
3. Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Palesch Y, Biro C, et al. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. *J Rheumatol*. 1997;24(5):879-89. Epub 1997/05/01. PubMed PMID: 9150076.
4. Ingegnoli F, Gualtierotti R, Orenti A, Schioppo T, Marfia G, Campanella R, et al. Uniphasic Blanching of the Fingers, Abnormal Capillaroscopy in Nonsymptomatic Digits, and Autoantibodies: Expanding Options to Increase the Level of Suspicion of Connective Tissue Diseases beyond the Classification of Raynaud's Phenomenon. *J Immunol Res*. 2015;2015:371960. doi: 10.1155/2015/371960. PubMed PMID: 26075287; PubMed Central PMCID: PMC4449942.
5. Schieir O, Thombs BD, Hudson M, Boivin JF, Steele R, Bernatsky S, et al. Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. *Arthritis Care Res (Hoboken)*. 2010;62(3):409-17. doi: 10.1002/acr.20108. PubMed PMID: 20391488.
6. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. *Arthritis Rheum*. 2002;46(9):2410-20. Epub 2002/10/02. doi: 10.1002/art.10486. PubMed PMID: 12355489.
7. Stamm T, Hieblinger R, Bostrom C, Mihai C, Birrell F, Thorstensson C, et al. Similar problem in the activities of daily living but different experience: a qualitative analysis in six rheumatic conditions and eight European countries. *Musculoskeletal Care*. 2014;12(1):22-33. doi: 10.1002/msc.1047. PubMed PMID: 23362188.
8. Kocher A, Adler S, Spichiger E. Skin and mucosa care in systemic sclerosis--patients' and family caregivers' experiences and expectations of a specific education programme: a qualitative study. *Musculoskeletal Care*. 2013;11(3):168-78. doi: 10.1002/msc.1051. PubMed PMID: 23532980.

9. Suarez-Almazor ME, Kallen MA, Roundtree AK, Mayes M. Disease and symptom burden in systemic sclerosis: a patient perspective. *J Rheumatol.* 2007;34(8):1718-26. PubMed PMID: 17611983.
10. Cinar FI, Unver V, Yilmaz S, Cinar M, Yilmaz F, Simsek I, et al. Living with scleroderma: patients' perspectives, a phenomenological study. *Rheumatol Int.* 2012;32(11):3573-9. doi: 10.1007/s00296-011-2230-2. PubMed PMID: 22090008.
11. Raynaud MTbB, T.). *Selected Monographs: Raynaud's two essays on Local Asphyxia of the Extremities.* London: The New Sydenham Society; 1888.
12. Maricq HR, Weinrich MC, Keil JE, LeRoy EC. Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. *J Chronic Dis.* 1986;39(6):423-7. PubMed PMID: 3711250.
13. Brennan P, Silman A, Black C, Bernstein R, Coppock J, Maddison P, et al. Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group. *Br J Rheumatol.* 1993;32(5):357-61. Epub 1993/05/01. PubMed PMID: 8495253.
14. LeRoy EC, Medsger TA, Jr. Raynaud's phenomenon: a proposal for classification. *Clin Exp Rheumatol.* 1992;10(5):485-8. Epub 1992/09/11. PubMed PMID: 1458701.
15. LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. *J Rheumatol.* 2001;28(7):1573-6. Epub 2001/07/27. PubMed PMID: 11469464.
16. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. *Arthritis Rheum.* 2013;65(11):2737-47. doi: 10.1002/art.38098. PubMed PMID: 24122180; PubMed Central PMCID: PMC3930146.
17. Maverakis E, Patel F, Kronenberg DG, Chung L, Fiorentino D, Allanore Y, et al. International consensus criteria for the diagnosis of Raynaud's phenomenon. *J Autoimmun.* 2014;48-49:60-5. doi: 10.1016/j.jaut.2014.01.020. PubMed PMID: 24491823; PubMed Central PMCID: PMC4018202.
18. Maricq HR, Weinrich MC. Diagnosis of Raynaud's phenomenon assisted by color charts. *J Rheumatol.* 1988;15(3):454-9. PubMed PMID: 3379622.
19. Wollersheim H, Thien T. The diagnostic value of clinical signs and symptoms in patients with Raynaud's phenomenon. A cross-sectional study. *Neth J Med.* 1990;37(5-6):171-82. Epub 1990/12/01. PubMed PMID: 2074908.
20. Schneeberger D, Tyndall A, Kay J, Sondergaard KH, Carreira PE, Morgiel E, et al. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. *Rheumatology (Oxford).* 2013;52(3):560-7. doi: 10.1093/rheumatology/kes315. PubMed PMID: 23221323.
21. Cardelli MB, Kleinsmith DM. Raynaud's phenomenon and disease. *Med Clin North Am.* 1989;73(5):1127-41. PubMed PMID: 2671536.
22. Chikura B, Moore TL, Manning JB, Vail A, Herrick AL. Sparing of the thumb in Raynaud's phenomenon. *Rheumatology (Oxford).* 2008;47(2):219-21. Epub 2008/01/23. doi: 10.1093/rheumatology/kem353. PubMed PMID: 18208825.
23. Chikura B, Moore T, Manning J, Vail A, Herrick AL. Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease. *J Rheumatol.* 2010;37(4):783-6. Epub 2010/03/03. doi: jrheum.091117 [pii] 10.3899/jrheum.091117. PubMed PMID: 20194444.
24. Watson HR, Robb R, Belcher G, Belch JJ. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis. *J Rheumatol.* 1999;26(8):1734-7. PubMed PMID: 10451070.
25. Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL. Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception. *Rheumatology (Oxford).* 2015;54(8):1443-7. doi: 10.1093/rheumatology/kev002. PubMed PMID: 25752312.
26. Freedman RR, Ianni P. Role of cold and emotional stress in Raynaud's disease and scleroderma. *Br Med J (Clin Res Ed).* 1983;287(6404):1499-502. PubMed PMID: 6416474; PubMed Central PMCID: PMC1549944.

27. Freedman RR, Ianni P. Effects of general and thematically relevant stressors in Raynaud's disease. *J Psychosom Res.* 1985;29(3):275-80. PubMed PMID: 4032326.
28. Freedman RR, Ianni P, Wenig P. Behavioral treatment of Raynaud's disease. *J Consult Clin Psychol.* 1983;51(4):539-49. PubMed PMID: 6619361.
29. Harrison BJ, Silman AJ, Hider SL, Herrick AL. Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. *Arthritis Rheum.* 2002;46(12):3312-6. Epub 2002/12/17. doi: 10.1002/art.10685. PubMed PMID: 12483737.
30. Hudson M, Lo E, Lu Y, Hercz D, Baron M, Steele R, et al. Cigarette smoking in patients with systemic sclerosis. *Arthritis Rheum.* 2011;63(1):230-8. doi: 10.1002/art.30071. PubMed PMID: 20936633.
31. Wigley FM, Korn JH, Csuka ME, Medsger TA, Jr., Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. *Arthritis Rheum.* 1998;41(4):670-7. Epub 1998/04/29. doi: 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I. PubMed PMID: 9550476.
32. Black CM, Halkier-Sorensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. *Br J Rheumatol.* 1998;37(9):952-60. Epub 1998/10/23. PubMed PMID: 9783759.
33. Schioppa E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. *J Rheumatol.* 2009;36(10):2264-8. doi: 10.3899/jrheum.090270. PubMed PMID: 19755613.
34. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA, Jr., et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. *Ann Intern Med.* 1994;120(3):199-206. Epub 1994/02/01. PubMed PMID: 7506013.
35. Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. *Rheumatology (Oxford).* 2010;49(12):2420-8. doi: 10.1093/rheumatology/keq291. PubMed PMID: 20837499.
36. Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O'Connell D, et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. *Arthritis Rheum.* 2011;63(3):775-82. doi: 10.1002/art.30195. PubMed PMID: 21360507.
37. Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. *Arthritis Rheum.* 2009;60(3):870-7. doi: 10.1002/art.24351. PubMed PMID: 19248104.
38. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. *Circulation.* 2005;112(19):2980-5. doi: 10.1161/CIRCULATIONAHA.104.523324. PubMed PMID: 16275885.
39. Pauling JD, Shipley JA, Hart DJ, McGrogan A, McHugh NJ. Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary. *J Rheumatol.* 2015;42(7):1163-8. doi: 10.3899/jrheum.141437. PubMed PMID: 26034146.
40. Mendelson C, Poole JL, Allaire S. Experiencing work as a daily challenge: the case of scleroderma. *Work.* 2013;44(4):405-13. doi: 10.3233/WOR-2012-1420. PubMed PMID: 22927612.
41. Mendelson C, Poole JL. Become your own advocate: advice from women living with scleroderma. *Disabil Rehabil.* 2007;29(19):1492-501. doi: 10.1080/09638280601029480. PubMed PMID: 17852224; PubMed Central PMCID: PMC2768647.
42. Gladue H, Maranian P, Paulus HE, Khanna D. Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials. *Arthritis Care Res (Hoboken).* 2013;65(4):630-6. doi: 10.1002/acr.21858. PubMed PMID: 22972592; PubMed Central PMCID: PMC3529989.

43. Pauling JD FT, Hughes, M, Gordon, JK, Domsic, RT, Ingegnoli, F, McHugh, NM, Johnson, SR, Hudson, M, Boin, F, Ong, V, Matucci Cerinic, M, Altork, N, Scolnik, M, Nikpour, M, Shah, A, Pope, JE, Khanna, D, Herrick, AL. Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud's Phenomenon in Systemic Sclerosis. *Arthritis Rheumatol.* 2016;68 (suppl 10).
44. Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. *Ann Rheum Dis.* 2013;72(10):1696-9. doi: 10.1136/annrheumdis-2012-202836. PubMed PMID: 23426043.
45. Belch JJ. Raynaud's phenomenon: its relevance to scleroderma. *Ann Rheum Dis.* 1991;50 Suppl 4:839-45. PubMed PMID: 1750795; PubMed Central PMCID: PMC1033318.
46. Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. *Ann Rheum Dis.* 2010;69(3):588-91. doi: 10.1136/ard.2009.107706. PubMed PMID: 19364728; PubMed Central PMCID: PMC2837770.
47. Bacher A, Mittoo S, Hudson M, Tatibouet S, Canadian Scleroderma Research G, Baron M. Systemic sclerosis in Canada's North American Native population: assessment of clinical and serological manifestations. *J Rheumatol.* 2013;40(7):1121-6. doi: 10.3899/jrheum.121212. PubMed PMID: 23678158.
48. Willems LM, Kwakkenbos L, Leite CC, Thombs BD, van den Hoogen FH, Maia AC, et al. Frequency and impact of disease symptoms experienced by patients with systemic sclerosis from five European countries. *Clin Exp Rheumatol.* 2014;32(6 Suppl 86):S-88-93. PubMed PMID: 25372793.
49. Bassel M, Hudson M, Taillefer SS, Schieir O, Baron M, Thombs BD. Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. *Rheumatology (Oxford).* 2011;50(4):762-7. doi: 10.1093/rheumatology/keq310. PubMed PMID: 21149249.
50. Leite CC, Maia A. Symptoms of disease and psychological adaptation in Brazilian scleroderma patients. *Rev Bras Reumatol.* 2013;53(5):405-11. PubMed PMID: 24316897.
51. Sandqvist G, Hesselstrand R, Eberhardt K. A longitudinal follow-up of hand involvement and activities of daily living in early systemic sclerosis. *Scand J Rheumatol.* 2009;38(4):304-10. doi: 10.1080/03009740802695466. PubMed PMID: 19296402.
52. Nguyen VA, Eisendle K, Gruber I, Hugi B, Reider D, Reider N. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. *Rheumatology (Oxford).* 2010;49(3):583-7. doi: 10.1093/rheumatology/kep413. PubMed PMID: 20040526.
53. Steen VD, Medsger TA, Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. *Arthritis Rheum.* 1997;40(11):1984-91. doi: 10.1002/1529-0131(199711)40:11<1984::AID-ART10>3.0.CO;2-R. PubMed PMID: 9365087.
54. Frantz C, Avouac J, Distler O, Amrouche F, Godard D, Kennedy AT, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. *Semin Arthritis Rheum.* 2016;46(1):115-23. doi: 10.1016/j.semarthrit.2016.02.005. PubMed PMID: 27132536.
55. Stamm TA, Mattsson M, Mihai C, Stocker J, Binder A, Bauernfeind B, et al. Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries. *Ann Rheum Dis.* 2011;70(6):1074-9. doi: 10.1136/ard.2010.148767. PubMed PMID: 21540204; PubMed Central PMCID: PMC3086051.
56. Jewett LR, Malcarne VL, Kwakkenbos L, Harcourt D, Rumsey N, Korner A, et al. Development and Validation of the Body Concealment Scale for Scleroderma. *Arthritis Care Res (Hoboken).* 2016;68(8):1158-65. doi: 10.1002/acr.22819. PubMed PMID: 26663624.
57. Sandqvist G, Hesselstrand R, Scheja A, Hakansson C. Managing work life with systemic sclerosis. *Rheumatology (Oxford).* 2012;51(2):319-23. doi: 10.1093/rheumatology/ker324. PubMed PMID: 22019802.

58. Herrgott I, Riemekasten G, Hunzelmann N, Sunderkotter C. Management of cutaneous vascular complications in systemic scleroderma: experience from the German network. *Rheumatol Int.* 2008;28(10):1023-9. doi: 10.1007/s00296-008-0556-1. PubMed PMID: 18320192.
59. Walker KM, Pope J, participating members of the Scleroderma Clinical Trials C, Canadian Scleroderma Research G. Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. *Semin Arthritis Rheum.* 2012;42(1):42-55. doi: 10.1016/j.semarthrit.2012.01.003. PubMed PMID: 22464314.
60. Harding S, Khimdas S, Bonner A, Baron M, Pope J, Canadian Scleroderma Research G. Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG). *Clin Exp Rheumatol.* 2012;30(2 Suppl 71):S38-43. PubMed PMID: 22691207.
61. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis.* 2017;76(8):1327-39. doi: 10.1136/annrheumdis-2016-209909. PubMed PMID: 27941129.
62. Pope J, Harding S, Khimdas S, Bonner A, Canadian Scleroderma Research G, Baron M. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. *J Rheumatol.* 2012;39(3):524-31. doi: 10.3899/jrheum.110121. PubMed PMID: 22247347.
63. Moinzadeh P, Riemekasten G, Siegert E, Fierlbeck G, Henes J, Blank N, et al. Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. *J Rheumatol.* 2016;43(1):66-74. doi: 10.3899/jrheum.150382. PubMed PMID: 26568599.

Figure 1. Acrocyanosis in the digits of a patient with limited cutaneous systemic sclerosis.

In addition to the typical cyanosis of SSc-RP, there is also evidence of active digital ulceration affecting the right thumb tip and digital pitting affecting the right 4th digit, left thumb and left 5th digit.



Table 1. Existing patient and clinician-reported outcome instruments for assessing SSc-RP

* Sometimes adapted from its original form as a 0-100mm VAS with mean values obtained over 1 week of assessment

Name	Study	Item metric	Recall Period	Score	Item Wording
Patient-Reported Outcomes					
Raynaud's Severity Scale	Wigley et al. 1994	11-point NRS (0-10)	1 day	Mean daily score over 3-week period	Patients were asked to consider in their and duration of attacks; symptoms, such as tingling; hand disability; and influence of attacks defined as an episode of pallor followed by associated pain.
Raynaud's Condition Score	Black et al. 1998	11-point NRS (0-10); 0 None – 10 very severe	1 day	Mean daily score over 2-week period*	Please rate the difficulty you had today with your Raynaud's. Consider the following when choosing your score: the duration of the attacks; when they occurred; numbness, burning and tingling, and the impact on your hands and to perform other activities.
Raynaud's Condition Score	Wigley et al. 1998	11-point NRS (0-10); 0 No difficulty -10 Extreme difficulty*	1 day	aily score over 2-week	The Raynaud's Condition Score is your rating of how difficult it was with your Raynaud's TODAY. Consider how long they lasted. Consider how much pain Raynaud's caused in your fingers (including numbness, burning and tingling). Raynaud's ALONE affected the use of your hands.
Patient Global Assessment	Wigley et al. 1998	0-15cm VAS; (0 no disease activity and 100 very severe)	7 days	15cm re-scaled to continuous 0-3 scale to match SHAQ	In the past week, how severe was your Raynaud's?
SHAQ RP VAS Subscale	Steen & Medsger 1997	0-15cm VAS; (0 does not interfere and 100 very severe)	7 days	15cm re-scaled to continuous 0-3 scale	In the past week how much have your Raynaud's interfered with your activities?
Clinician-Reported Outcomes					
Physician Global Assessment	Wigley et al. 1994	4-point NRS (0-3)	7 days or 1 day	Score either on day of assessment or taking into account last 7 days	The study physician evaluated the severity of Raynaud's using a scoring system in which 0 represented a mild attack, 2 represented a moderate attack, and 3 represented a severe attack.
Physician Global Assessment	Wigley et al. 1998	0-15cm VAS; (anchored at 0 no disease activity and at 100 very severe disease activity)	7 days	15cm re-scaled to continuous 0-3 scale to match SHAQ	"How severe would you rate the patient's Raynaud's over the past week?"